This article summarized the latest R&D progress of dorzolamide hydrochloride, the Mechanism of Action for dorzolamide hydrochloride, and the drug target R&D trends for dorzolamide hydrochloride.

Disc Medicine has revealed the start of a Phase 1 trial for DISC-3405 (formerly MWTX-003) with healthy participants.

This article summarized the latest R&D progress of dorzagliatin, the Mechanism of Action for dorzagliatin, and the drug target R&D trends for dorzagliatin.

Complete response (CR) is defined as the absence of detectable tumor in the patient's body. Radiology and histopathology are used to measure CR, serving as surrogate or primary endpoints depending on the specific disease or use scenario.

Kineta, Inc., a clinical-stage biotech firm specializing in unique cancer immunotherapies, has shared updates on their ongoing Phase 1/2 clinical trial of KVA12123 for advanced solid tumor patients.

Duration of Response (DoR) is defined as the time from randomization to disease progression or death for patients who achieve complete or partial alleviation.

Oncolytic virus (OVs) refers to a generic name for viruses that naturally exist or are genetically edited to selectively kill tumor cells.

This article summarized the latest R&D progress of dobutamine hydrochloride, the Mechanism of Action for dobutamine hydrochloride, and the drug target R&D trends for dobutamine hydrochloride.

Clarity Pharmaceuticals proudly announces the initial patient dosing in their 64Cu/67Cu SAR-Bombesin Phase I/II theranostic trial for patients with metastatic castrate resistant prostate cancer.

Duration of Clinical Benefit (DoCB) is defined as the time from randomization to disease progression or death in patients who achieve complete remission, partial remission, or disease stability for 24 weeks or longer.

REGENXBIO Inc. disclosed further provisional safety information and preliminary effectiveness results from the phase I/II AFFINITY DUCHENNE™ study of RGX-202 aimed at treating Duchenne Muscular Dystrophy.

This article summarized the latest R&D progress of disopyramide phosphate, the Mechanism of Action for disopyramide phosphate, and the drug target R&D trends for disopyramide phosphate.